Lilly seeks niche for its blood-thinner Effient - Indianapolis Star

As if going up against one of the best-selling drugs ever wasn't challenging enough. Now Eli Lilly and Co.'s blood-thinner Effient has it even tougher. Its chief rival, Plavix, has gone generic in the U.S. This week, low-priced knockoffs will ...

Potential Effient rival recommended for approval - Ibj.com

Johnson & Johnson and Bayer AG’s blood-thinner Xarelto should be approved to help prevent heart attacks and strokes in patients with a common condition, a U.S. regulatory report recommended. The drug works in patients with acute coronary syndrome, which ...

Plavix's Loss Means Little Gain by Rival Blood Thinners - Bloomberg

Lilly’s Effient and AstraZeneca’s Brilinta will be used mostly by new patients who are beginning therapy, said Barbara Ryan, an analyst with Deutsche Bank who has a buy rating on New York-based Bristol-Myers’s stock. Plavix, and now the ...

FDA Approves Generic Clopidogrels As Plavix Loses Patent Protection - Forbes

However, these drugs, prasugrel (Effient) and ticagrelor (Brilinta) have been struggling in the marketplace, and at this point appear very unlikely to command a significant share of the market. Here is the FDA press release: FDA approves generic ...

Accumetrics Sees Significantly Increased Interest in VerifyNow P2Y12 Test as Plavix(R) Loses Patent Protection - Marketwatch

In fact, several health plans across the nation have already created prior authorization requirements for the more potent branded drugs, Effient(R) and Brilinta(R), with clopidogrel non-responsiveness as justification for prescribing them.

Plavix's New Generic Status Could Be Boon for Patients - YAHOO!

In addition, new drugs are available that may be better than Plavix, Fonarow said. "Newer antiplatelet agents, such as prasugrel (Effient) and ticagrelor (Brilinta), have been shown to be more [effective] than clopidogrel, and for many patients these ...

Approval of Generic Clopidogrel a Boon for Patients or Payors? - familypracticenews.com

prasugrel (Effient) and ticagrelor (Brilinta). “It is possible that the large payers will require genetic or platelet function testing proof of poor clopidogrel responsiveness before they agree to pay for prasugrel or ticagrelor,” he said in an interview.

"Germany Pharmaceuticals & Healthcare Report Q2 2012" Now Available at Fast Market Research - SBWire

and Eli Lilly/Daiichi Sankyo's Effient (prasugrel). - In January 2012, in negative news for multinational drugmakers Eli Lilly and Boehringer Ingelheim, Trajenta (linagliptin) for patients with type 2 diabetes did not pass the Institute for Quality and ...